A Phase 2 Single Arm Study of Elotuzumab in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Multiple Myeloma Relapsed or Refractory to Prior Treatment with Lenalidomide

ID Number 16-0648

Principal Investigator(s)
Sundar Jagannath

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to determine the safety and effectiveness (how well the drug works) of the experimental new drug elotuzumab in combination with pomalidomide and low dose dexamethasone for the treatment of multiple myeloma patients who have relapsed after or are refractory to a prior treatment with a lenalidomide-based regimen.

Contact Information
Lisa La
Recruiting Patients: Yes